Clinical Trial Update: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC [Phase 2]

View source ↗

Summary

This entry reports on a Phase II trial investigating ctDNA-guided retreatment with encorafenib plus cetuximab in patients with BRAF V600E-mutated metastatic col…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Encorafenib (encorafenib)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING